Rustenbeck, Hans-Heino

[["dc.bibliographiccitation.firstpage","442"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","American Journal of Neuroradiology"],["dc.bibliographiccitation.lastpage","446"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Buhk, J.-H."],["dc.contributor.author","Elolf, Erck"],["dc.contributor.author","Jacob, Dorrit E."],["dc.contributor.author","Rustenbeck, H.-H."],["dc.contributor.author","Mohr, A."],["dc.contributor.author","Knauth, Michael"],["dc.date.accessioned","2018-11-07T11:17:17Z"],["dc.date.available","2018-11-07T11:17:17Z"],["dc.date.issued","2008"],["dc.description.abstract","BACKGROUND AND PURPOSE: The purpose of this work was to provide an intraindividual comparison of angiographic CT (ACT) and multisection CT (MSCT) in lumbar myelographic imaging and to evaluate possible benefits of ACT, which is a further development of rotational angiography providing image data of high spatial and CT-like contrast resolution. MATERIALS AND METHODS: In 26 patients with degenerative lumbar spine disease a lumbar ACT was performed in combination with conventional lumbar myelography and followed by postmyelographic. MSCT. Conventional lumbar myelography and lumbar ACT were performed with a flat panel detector-equipped angiographic device. Postmyelographic MSCT was performed with a 16-section CT scanner. Three experienced neuroradiologists rated anonymized sets of multiplanar reformatted CT and ACT images regarding diagnostic and technical parameters. The ratings were repeated after 2 months. Weighted K Statistics were calculated to describe the levels of intraobserver and interobserver agreement. RESULTS: The analysis shows that MSCT achieves higher ratings than ACT in all of the parameters asked. An adequate diagnostic quality was only assigned to 80% of the ACT acquisitions compared with 97% of the MSCT acquisitions. All of the mean K values were above 0.60, demonstrating a substantial intraobserver and interobserver agreement for MSCT, as well as for ACT. CONCLUSION: Using ACT, radiographic myelography and myelographic CT can be performed at the same imaging system. However, the results of our study show that the current myelographic ACT image quality fails to apply diagnostic standards. We, therefore, cannot recommend ACT as a general alternative to postmyelographic MSCT."],["dc.identifier.doi","10.3174/ajnr.A0853"],["dc.identifier.isi","000254066700008"],["dc.identifier.pmid","18065508"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54769"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Neuroradiology"],["dc.relation.issn","0195-6108"],["dc.title","A comparison of angiographic CT and multisection CT in lumbar myelographic imaging"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","307"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Oral and Maxillofacial Surgery"],["dc.bibliographiccitation.lastpage","309"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Brandt, Andreas"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Rustenbeck, Hans"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Laskawi, Rainer"],["dc.date.accessioned","2019-07-09T11:39:48Z"],["dc.date.available","2019-07-09T11:39:48Z"],["dc.date.issued","2013"],["dc.description.abstract","Possible complications of parotid gland surgery are numerous, just as the reasons for aneurysms of the superficial temporal artery. The occurrence of such an aneurysm as a consequence of parotidectomy, however, has so far only been published once. Here, we report of an aneurysm of the superficial temporal artery following parotid gland surgery. It presented as a pulsating mass in the preauricular region. Combining clinical examination, duplex ultrasound, and CT scan, the diagnosis was readily established and treated with a circumscribed revision at low risk and without complications."],["dc.identifier.doi","10.1007/s10006-012-0385-y"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10320"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58039"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","Springer"],["dc.publisher.place","Berlin/Heidelberg"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Aneurysm of the superficial temporal artery following parotid gland surgery-Case report and review of the literature"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","888"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","+"],["dc.bibliographiccitation.volume","74"],["dc.contributor.author","Schmidt, H."],["dc.contributor.author","Kaboth, U."],["dc.contributor.author","Brinck, Ulrich"],["dc.contributor.author","Ratzka, P."],["dc.contributor.author","Rustenbeck, Hans Heino"],["dc.contributor.author","Nau, R."],["dc.date.accessioned","2018-11-07T10:35:55Z"],["dc.date.available","2018-11-07T10:35:55Z"],["dc.date.issued","2003"],["dc.description.abstract","Up to 40% of patients with malignant thymoma suffer from paraneoplastic symptoms (90% myasthenia, 10% other symptoms). A 55-year-old patient developed ascending symmetrical, sensorimotor tetraparesis. A malignant thymoma without metastases was diagnosed 6 months, later. Despite thymectomy followed by radiation and high-dose corticosteroid therapy, the, polyneuropathy progressed. Six months after onset, the patient was bound to a wheelchair. Immunosuppressive therapy with cyclophosphamide was initiated, leading to marked remission. After ten cycles, the patient was able to walk independently with walking aids. After the sixth and tenth cycle, respectively, attempts to discontinue immunosuppression led to relapse. In several diagnostic workups, however, there was no tumour relapse. After 13 cycles, cyclophosphamide was replaced by immunoglobulins (0.4 g/kg per day i.v. for 5 days/month) due to progressive renal failure. The patient died just before the secondcourse of this treatment. In conclusion, in the differential diagnosis of rapidly progressive polyneuropathy a malignant thymoma should be considered, even in the absence of myasthenia. Immunosuppression with cyclophosphamide resulted in amelioration of symptoms in this patient."],["dc.identifier.doi","10.1007/s00115-003-1552-z"],["dc.identifier.isi","000186443000009"],["dc.identifier.pmid","14551694"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45203"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0028-2804"],["dc.title","Polyneuropathy as a sole syndrome in mialignant thymoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Stroke"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Hasselblatt, M."],["dc.contributor.author","Piotr, L."],["dc.contributor.author","Dembowski, C."],["dc.contributor.author","Cepek, L."],["dc.contributor.author","Stiefel, M."],["dc.contributor.author","Rustenbeck, Hans Heino"],["dc.contributor.author","Jacob, S."],["dc.contributor.author","Knerlich, F."],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Prange, Hilmar"],["dc.contributor.author","Siren, A. L."],["dc.date.accessioned","2018-11-07T10:33:49Z"],["dc.date.available","2018-11-07T10:33:49Z"],["dc.date.issued","2002"],["dc.format.extent","354"],["dc.identifier.isi","000173147700143"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44705"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.issn","0039-2499"],["dc.title","Erythropoietin treatment for acute stroke: A randomized double-blind proof-of concept trial in man"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Clinical Case Reports"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Giotaki, Ioanna"],["dc.contributor.author","Gross, Uwe"],["dc.contributor.author","Lange, Peter"],["dc.contributor.author","Rustenbeck, Hans-Heino"],["dc.contributor.author","Bahn, Erik"],["dc.contributor.author","Nau, Roland"],["dc.date.accessioned","2022-05-02T08:09:51Z"],["dc.date.available","2022-05-02T08:09:51Z"],["dc.date.issued","2022"],["dc.description.abstract","The outcome of chronic meningitis depends to a large degree on the causative pathogen and the interval between onset of symptoms and diagnosis. We present a patient with a delayed diagnosis and several complications, for whom adequate therapy resulted in a favorable outcome. In a 76-year-old male patient, Candida albicans meningitis was diagnosed 4 months after the onset of symptoms. CSF findings (protein >1000 mg/L, predominance of intrathecal immunoglobulin A synthesis, lactate concentrations of approx. 10 mmol/L, leukocyte counts around 1000/μl, variable differential leukocyte counts) resembled tuberculous meningitis. In spite of the long interval without treatment, voriconazole 200 mg every 12 h for 7 weeks followed by fluconazole 300 mg/day maintenance therapy for 7 months led to a recovery with only mild deficits. The case illustrates that 1. C. albicans can cause chronic meningitis in patients without severe immune defects, 2. patients can survive C. albicans meningitis with mild long-term sequelae even when diagnosis and adequate treatment are delayed, and 3. voriconazole as a sole agent may be suitable for treatment of C. albicans meningitis."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1002/ccr3.5664"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107483"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.eissn","2050-0904"],["dc.relation.issn","2050-0904"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","http://creativecommons.org/licenses/by-nc/4.0/"],["dc.title","Chronic Candida albicans meningitis misdiagnosed as polymyalgia rheumatica and successfully treated with voriconazole"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","HNO"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Ihler, F."],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Rustenbeck, Hans Heino"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T09:05:10Z"],["dc.date.available","2018-11-07T09:05:10Z"],["dc.date.issued","2012"],["dc.format.extent","905"],["dc.identifier.doi","10.1007/s00106-012-2603-1"],["dc.identifier.isi","000309480200010"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25259"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0017-6192"],["dc.title","Use of Botulinum Toxin A after microvascular ALT Flaps in a patient with Tongue and Floor of mouth carcinoma (vol 60, pg 524, 2012)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","169"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Pediatric Radiology"],["dc.bibliographiccitation.lastpage","172"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Papos, M."],["dc.contributor.author","Pekrun, Arnulf"],["dc.contributor.author","Herms, J. W."],["dc.contributor.author","Behr, T. M."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Rustenbeck, Hans Heino"],["dc.contributor.author","Kretzschmar, Hans A."],["dc.contributor.author","Becker, W."],["dc.date.accessioned","2018-11-07T09:20:56Z"],["dc.date.available","2018-11-07T09:20:56Z"],["dc.date.issued","2001"],["dc.description.abstract","A 10-year-old girl presented with a cerebral malignant ectomesenchymoma (MEM), a very unusual tumour with undifferentiated mesenchymal as well as ectodermal elements. Somatostatin receptor scintigraphy (SRS) was performed during the diagnostic workup. The recurrent residual tumour mass was exactly visualized with SRS, and was negative after successful treatment of the patient. The potential application of SRS in initial staging, follow-up and therapy planning in MEM is discussed. This is the first application of SRS in MEM."],["dc.identifier.doi","10.1007/s002470000404"],["dc.identifier.isi","000167350300008"],["dc.identifier.pmid","11297080"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28993"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0301-0449"],["dc.title","Somatostatin receptor scintigraphy in the management of cerebral malignant ectomesenchymoma: a case report"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","495"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Molecular Medicine"],["dc.bibliographiccitation.lastpage","505"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Ehrenreich, Hannelore"],["dc.contributor.author","Hasselblatt, Martin"],["dc.contributor.author","Dembowski, Christoph"],["dc.contributor.author","Cepek, Lukas"],["dc.contributor.author","Lewczuk, Pjotr"],["dc.contributor.author","Stiefel, Michael"],["dc.contributor.author","Rustenbeck, Hans-Heino"],["dc.contributor.author","Breiter, Norbert"],["dc.contributor.author","Jacob, Sonja"],["dc.contributor.author","Knerlich, Friederike"],["dc.contributor.author","Bohn, Matthias"],["dc.contributor.author","Poser, Wolfgang"],["dc.contributor.author","Rüther, Eckart"],["dc.contributor.author","Kochen, Michael"],["dc.contributor.author","Gefeller, Olaf"],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Wessel, Thomas C."],["dc.contributor.author","Ryck, Marc de"],["dc.contributor.author","Itri, Loretta"],["dc.contributor.author","Prange, Hilmar"],["dc.contributor.author","Cerami, Anthony"],["dc.contributor.author","Brines, Michael"],["dc.contributor.author","Siren, Anna-Leena"],["dc.date.accessioned","2017-09-07T11:45:41Z"],["dc.date.available","2017-09-07T11:45:41Z"],["dc.date.issued","2002"],["dc.description.abstract","Background: Erythropoietin (EPO) and its receptor play a major role in embryonic brain, are weakly expressed in normal postnatal/adult brain and up-regulated upon metabolic stress. EPO protects neurons from hypoxic/ ischemic injury. The objective of this trial is to study the safety and efficacy of recombinant human EPO (rhEPO) for treatment of ischemic stroke in man. Materials and Methods: The trial consisted of a safety part and an efficacy part. in the safety study, 13 patients received rhEPO intravenously (3.3 x 10(4) IU/50 m/130 min) once daily for the first 3 days after stroke. in the double-blind randomized proof-of-concept trial, 40 patients received either rhEPO or saline. Inclusion criteria were age {.extbackslash}textless80 years, ischemic stroke within the middle cerebral artery territory confirmed by diffusion-weighted MRI, symptom onset {.extbackslash}textless8 hr before drug administration, and deficits on stroke scales. The study endpoints were functional outcome at day 30 (Barthel index, modified Rankin scale), NIH and Scandinavian stroke scales, evolution of infarct size (sequential MRI evaluation using diffusion-weighted [DWI] and fluid-attenuated inversion recovery sequences [FLAIR]) and the damage marker S100ss. Results: No safety concerns were identified. Cerebrospinal fluid EPO increased to 60-100 times that of nontreated patients, proving that intravenously administered rhEPO reaches the brain. in the efficacy trial, patients received rhEPO within 5 hr of onset of symptoms (median, range 2:40-7:55). Admission neurologic scores and serum S100beta concentrations were strong predictors of outcome. Analysis of covariance controlled for these two variables indicated that rhEPO treatment was associated with an improvement in follow-up and outcome scales. A strong trend for reduction in infarct size in rhEPO patients as compared to controls was observed by MRI. Conclusion: intravenous high-dose rhEPO is well tolerated in acute ischemic stroke and associated with an improvement in clinical outcome at 1 month. A larger scale clinical trial is warranted."],["dc.identifier.gro","3150429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7192"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","1076-1551"],["dc.relation.orgunit","Institut für Allgemeinmedizin"],["dc.title","Erythropoietin therapy for acute stroke is both safe and beneficial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","810"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","812"],["dc.bibliographiccitation.volume","254"],["dc.contributor.author","Arlt, Soenke"],["dc.contributor.author","Cepek, Lukas"],["dc.contributor.author","Rustenbeck, Hans Heino"],["dc.contributor.author","Prange, Hilmar"],["dc.contributor.author","Reimers, Carl Detlev"],["dc.date.accessioned","2018-11-07T11:01:59Z"],["dc.date.available","2018-11-07T11:01:59Z"],["dc.date.issued","2007"],["dc.identifier.doi","10.1007/s00415-006-0439-x"],["dc.identifier.isi","000247654300019"],["dc.identifier.pmid","17401744"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51272"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0340-5354"],["dc.title","Gadolinium encephalopathy due to accidental intrathecal administration of gadopentetate dimeglumine"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","524"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HNO"],["dc.bibliographiccitation.lastpage","527"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Ihler, F."],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Rustenbeck, Hans Heino"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T09:09:48Z"],["dc.date.available","2018-11-07T09:09:48Z"],["dc.date.issued","2012"],["dc.description.abstract","We report the case of a 23-year-old man presenting with a cT4 cN1 M0squamous cell carcinoma of the right tongue. After tumor resection and covering of the defect with a microvascular anterolateral thigh (ALT) flap, the patient showed distinct drooling without any substantial regression after anticholinergic therapy. For this reason 75 units of BotoxA (R) were injected into the submandibular and parotid glands. After the intraglandular injections, good reduction of saliva secretion was achieved. The treatment improved flap healing, aspiration and patient satisfaction. Injection of botulinum toxin A into the salivary glands is a sufficient therapy for postoperative hypersalivation."],["dc.identifier.doi","10.1007/s00106-011-2476-8"],["dc.identifier.isi","000304876600010"],["dc.identifier.pmid","22534678"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26347"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0017-6192"],["dc.title","Botulinum toxin A after microvascular ALT flap in a patient with squamous cell carcinoma of the tongue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]